298 related articles for article (PubMed ID: 27248434)
1. An Overview of Mouse Models of Nonalcoholic Steatohepatitis: From Past to Present.
Jacobs A; Warda AS; Verbeek J; Cassiman D; Spincemaille P
Curr Protoc Mouse Biol; 2016 Jun; 6(2):185-200. PubMed ID: 27248434
[TBL] [Abstract][Full Text] [Related]
2. Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis.
Verbeek J; Jacobs A; Spincemaille P; Cassiman D
Curr Protoc Mouse Biol; 2016 Jun; 6(2):201-210. PubMed ID: 27248435
[TBL] [Abstract][Full Text] [Related]
3. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
4. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
5. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
Nakajima T; Naito H
Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
[TBL] [Abstract][Full Text] [Related]
8. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
9. Experimental models of non-alcoholic fatty liver disease in rats.
Kucera O; Cervinkova Z
World J Gastroenterol; 2014 Jul; 20(26):8364-76. PubMed ID: 25024595
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
[TBL] [Abstract][Full Text] [Related]
11. Rodent Models of Nonalcoholic Fatty Liver Disease.
Zhong F; Zhou X; Xu J; Gao L
Digestion; 2020; 101(5):522-535. PubMed ID: 31600750
[TBL] [Abstract][Full Text] [Related]
12. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
13. Mouse models of nonalcoholic steatohepatitis in preclinical drug development.
Hansen HH; Feigh M; Veidal SS; Rigbolt KT; Vrang N; Fosgerau K
Drug Discov Today; 2017 Nov; 22(11):1707-1718. PubMed ID: 28687459
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
15. The FATZO mouse, a next generation model of type 2 diabetes, develops NAFLD and NASH when fed a Western diet supplemented with fructose.
Sun G; Jackson CV; Zimmerman K; Zhang LK; Finnearty CM; Sandusky GE; Zhang G; Peterson RG; Wang YJ
BMC Gastroenterol; 2019 Mar; 19(1):41. PubMed ID: 30885145
[TBL] [Abstract][Full Text] [Related]
16. Preclinical models of non-alcoholic fatty liver disease.
Santhekadur PK; Kumar DP; Sanyal AJ
J Hepatol; 2018 Feb; 68(2):230-237. PubMed ID: 29128391
[TBL] [Abstract][Full Text] [Related]
17. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
18. Clinical relevance of liver histopathology and different histological classifications of NASH in adults.
Nascimbeni F; Ballestri S; Machado MV; Mantovani A; Cortez-Pinto H; Targher G; Lonardo A
Expert Rev Gastroenterol Hepatol; 2018 Apr; 12(4):351-367. PubMed ID: 29224471
[TBL] [Abstract][Full Text] [Related]
19. Minimally invasive percutaneous endovascular therapies in the management of complications of non-alcoholic fatty liver disease (NAFLD): A case report.
Salsamendi J; Pereira K; Kang K; Fan J
J Radiol Case Rep; 2015 Sep; 9(9):36-43. PubMed ID: 26629307
[TBL] [Abstract][Full Text] [Related]
20. CD44 is a key player in non-alcoholic steatohepatitis.
Patouraux S; Rousseau D; Bonnafous S; Lebeaupin C; Luci C; Canivet CM; Schneck AS; Bertola A; Saint-Paul MC; Iannelli A; Gugenheim J; Anty R; Tran A; Bailly-Maitre B; Gual P
J Hepatol; 2017 Aug; 67(2):328-338. PubMed ID: 28323124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
